Bristol Lowers EPS Guidance On Plavix Decision
Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.
Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.